Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

Oyster Point Pharma logo

About Oyster Point Pharma Stock (NASDAQ:OYST)

Advanced Chart

Key Stats

Today's Range
$11.17
$11.17
50-Day Range
$11.08
$11.20
52-Week Range
$3.46
$19.00
Volume
330 shs
Average Volume
212,171 shs
Market Capitalization
$299.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

OYST Stock News Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Headlines

OYST Stock Analysis - Frequently Asked Questions

Oyster Point Pharma, Inc. (NASDAQ:OYST) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.48. The firm had revenue of $17.94 million for the quarter. Oyster Point Pharma had a negative net margin of 901.99% and a negative trailing twelve-month return on equity of 490.33%.

Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/04/2021
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-100,660,000.00
Net Margins
-901.99%
Pretax Margin
-901.99%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Price / Cash Flow
N/A
Book Value
$3.80 per share
Price / Book
2.94

Miscellaneous

Free Float
22,039,000
Market Cap
$299.85 million
Optionable
Not Optionable
Beta
1.31
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OYST) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners